Selected research
Industry Research
Granulocyte Macrophage Colony Stimulating Factor Industry Research Report 2026
Market perspective
The global Granulocyte Macrophage Colony Stimulating Factor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Granulocyte Macrophage Colony Stimulating Factor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Granulocyte Macrophage Colony Stimulating Factor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Granulocyte Macrophage Colony Stimulating Factor include Takeda Pharmaceutical Co Ltd, GlaxoSmithKline Plc, Amgen Inc, Sillajen Biotherapeutics, Morphotek Inc, Mologen AG, Humanigen Inc, Cold Genesys Inc and BriaCell Therapeutics Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Granulocyte Macrophage Colony Stimulating Factor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Granulocyte Macrophage Colony Stimulating Factor Market by Company
Takeda Pharmaceutical Co Ltd
GlaxoSmithKline Plc
Amgen Inc
Sillajen Biotherapeutics
Morphotek Inc
Mologen AG
Humanigen Inc
Cold Genesys Inc
BriaCell Therapeutics Corp
Aduro BioTech Inc
Granulocyte Macrophage Colony Stimulating Factor Segment by Type
CG-0070
Lenzilumab
Gimsilumab
MGN-1601
GSK-3196165
Others
Granulocyte Macrophage Colony Stimulating Factor Segment by Application
Solid Tumor
Kidney Cancer
Lymphoma
Lung Disease
Others
Granulocyte Macrophage Colony Stimulating Factor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte Macrophage Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granulocyte Macrophage Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte Macrophage Colony Stimulating Factor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Granulocyte Macrophage Colony Stimulating Factor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Granulocyte Macrophage Colony Stimulating Factor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Granulocyte Macrophage Colony Stimulating Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CG-0070
- Lenzilumab
- Gimsilumab
- MGN-1601
- GSK-3196165
- Others
Applications
- Solid Tumor
- Kidney Cancer
- Lymphoma
- Lung Disease
- Others
Companies covered
- Takeda Pharmaceutical Co Ltd
- GlaxoSmithKline Plc
- Amgen Inc
- Sillajen Biotherapeutics
- Morphotek Inc
- Mologen AG
- Humanigen Inc
- Cold Genesys Inc
- BriaCell Therapeutics Corp
- Aduro BioTech Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Market Size (2021-2032)
- 2.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales (2021-2032)
- 2.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Market Average Price (2021-2032)
- 2.3 Granulocyte Macrophage Colony Stimulating Factor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CG-0070
- 2.3.3 Lenzilumab
- 2.3.4 Gimsilumab
- 2.3.5 MGN-1601
- 2.3.6 GSK-3196165
- 2.3.7 Others
- 2.4 Granulocyte Macrophage Colony Stimulating Factor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Solid Tumor
- 2.4.3 Kidney Cancer
- 2.4.4 Lymphoma
- 2.4.5 Lung Disease
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Granulocyte Macrophage Colony Stimulating Factor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue of Manufacturers (2021-2026)
- 3.4 Global Granulocyte Macrophage Colony Stimulating Factor Average Price by Manufacturers (2021-2026)
- 3.5 Global Granulocyte Macrophage Colony Stimulating Factor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Granulocyte Macrophage Colony Stimulating Factor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Granulocyte Macrophage Colony Stimulating Factor, Product Type & Application
- 3.8 Global Manufacturers of Granulocyte Macrophage Colony Stimulating Factor, Established Date
- 3.9 Global Granulocyte Macrophage Colony Stimulating Factor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical Co Ltd
- 4.1.1 Takeda Pharmaceutical Co Ltd Company Information
- 4.1.2 Takeda Pharmaceutical Co Ltd Business Overview
- 4.1.3 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 Amgen Inc
- 4.3.1 Amgen Inc Company Information
- 4.3.2 Amgen Inc Business Overview
- 4.3.3 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.3.5 Amgen Inc Recent Developments
- 4.4 Sillajen Biotherapeutics
- 4.4.1 Sillajen Biotherapeutics Company Information
- 4.4.2 Sillajen Biotherapeutics Business Overview
- 4.4.3 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.4.5 Sillajen Biotherapeutics Recent Developments
- 4.5 Morphotek Inc
- 4.5.1 Morphotek Inc Company Information
- 4.5.2 Morphotek Inc Business Overview
- 4.5.3 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.5.5 Morphotek Inc Recent Developments
- 4.6 Mologen AG
- 4.6.1 Mologen AG Company Information
- 4.6.2 Mologen AG Business Overview
- 4.6.3 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.6.5 Mologen AG Recent Developments
- 4.7 Humanigen Inc
- 4.7.1 Humanigen Inc Company Information
- 4.7.2 Humanigen Inc Business Overview
- 4.7.3 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.7.5 Humanigen Inc Recent Developments
- 4.8 Cold Genesys Inc
- 4.8.1 Cold Genesys Inc Company Information
- 4.8.2 Cold Genesys Inc Business Overview
- 4.8.3 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.8.5 Cold Genesys Inc Recent Developments
- 4.9 BriaCell Therapeutics Corp
- 4.9.1 BriaCell Therapeutics Corp Company Information
- 4.9.2 BriaCell Therapeutics Corp Business Overview
- 4.9.3 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.9.5 BriaCell Therapeutics Corp Recent Developments
- 4.10 Aduro BioTech Inc
- 4.10.1 Aduro BioTech Inc Company Information
- 4.10.2 Aduro BioTech Inc Business Overview
- 4.10.3 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
- 4.10.5 Aduro BioTech Inc Recent Developments
5 Global Granulocyte Macrophage Colony Stimulating Factor Market Scenario by Region
- 5.1 Global Granulocyte Macrophage Colony Stimulating Factor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021-2032
- 5.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021-2026
- 5.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2027-2032
- 5.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region: 2021-2032
- 5.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region: 2021-2026
- 5.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region: 2027-2032
- 5.4 North America Granulocyte Macrophage Colony Stimulating Factor Market Facts & Figures by Country
- 5.4.1 North America Granulocyte Macrophage Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
- 5.4.3 North America Granulocyte Macrophage Colony Stimulating Factor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Granulocyte Macrophage Colony Stimulating Factor Market Facts & Figures by Country
- 5.5.1 Europe Granulocyte Macrophage Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
- 5.5.3 Europe Granulocyte Macrophage Colony Stimulating Factor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Granulocyte Macrophage Colony Stimulating Factor Market Facts & Figures by Country
- 5.7.1 South America Granulocyte Macrophage Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
- 5.7.3 South America Granulocyte Macrophage Colony Stimulating Factor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021-2032)
- 6.1.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Type (2021-2032)
- 6.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2021-2032)
- 6.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Type (2021-2032)
- 6.3 Global Granulocyte Macrophage Colony Stimulating Factor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021-2032)
- 7.1.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Application (2021-2032)
- 7.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2021-2032)
- 7.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Application (2021-2032)
- 7.3 Global Granulocyte Macrophage Colony Stimulating Factor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Granulocyte Macrophage Colony Stimulating Factor Value Chain Analysis
- 8.1.1 Granulocyte Macrophage Colony Stimulating Factor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Granulocyte Macrophage Colony Stimulating Factor Production Mode & Process
- 8.2 Granulocyte Macrophage Colony Stimulating Factor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Granulocyte Macrophage Colony Stimulating Factor Distributors
- 8.2.3 Granulocyte Macrophage Colony Stimulating Factor Customers
9 Global Granulocyte Macrophage Colony Stimulating Factor Analyzing Market Dynamics
- 9.1 Granulocyte Macrophage Colony Stimulating Factor Industry Trends
- 9.2 Granulocyte Macrophage Colony Stimulating Factor Industry Drivers
- 9.3 Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges
- 9.4 Granulocyte Macrophage Colony Stimulating Factor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst